NVDA’s $81.6B Quarter and the Options Setup That Followed
Record earnings, a 25x dividend hike, and elevated IV – here’s what the tape is saying right now
AMD Just Got Reframed — Here’s What the Citi Upgrade Actually Means for Traders
A closely watched analyst flips to Buy and the GPU math behind it is harder to ignore than the headline suggests.
The Power Stock AI Can’t Live Without
Vistra Energy is quietly cornering the market on something every data center desperately needs.
Marvell Just Got Called the Next Trillion-Dollar Company. Here’s What the Numbers Actually Say.
MRVL posted record revenue and a wave of analyst upgrades. The question is whether the tape has already priced the future.
Amazon’s Prime Day Is 12 Days Away. The Options Opportunity Isn’t Where Most Traders Are Looking.
AMZN moved Prime Day to June — earlier, longer, and with more at stake than any prior edition. Here’s the setup.
The Healthcare Sector Has Been Left for Dead. That’s the Setup Bargain Hunters Have Been Waiting For.
Three years of underperformance, a 20% valuation discount, and a mean-reversion case that’s getting harder to ignore.
The Chip Nobody Talked About — Until Jensen Huang Said Four Words
Marvell Technology is no longer flying under the radar, and the case for owning it goes well beyond one speech.
Salesforce Beat the Quarter, Then the Stock Sold Off. Here’s What the Options Market Already Knew.
CRM delivered record Q1 FY2027 results powered by Agentforce — but the price action tells a more complicated story that options traders were already pricing in.
GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.
Anthropic’s Near-Trillion Dollar IPO Filing Is Repricing Everything. Here’s What Investors Actually Own.
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn’t Anthropic — it’s what this does to the listed AI complex.